TheraCryf has released results for the year to March 2025 with the next 12-18 months set to be pivotal for the company as it focuses on advancing its Orexin-1 (Ox-1) programme while the Sulforaphane (SFX-01) programmes continue with third party funding. During FY25, the company acquired Chronos Therapeutics, making it a multi-compound drug developer, and raised a total of £5.2m, gross, funding the Ox-1 programme through to clinical readiness while extending TheraCryf's cash runway to 4Q 2026. The financial performance was in line with expectations, and the company ended FY25 with £4.1m in cash and short-term deposits. TheraCryf has since appointed Pharmaron as its pre-clinical development partner and manufacturing scale up of the Ox-1 compound has commenced. The Board has been strengthened with the appointment of new Chair, Dr Alastair Smith, and of Ed Wardle as Non-Executive Director.
